How Can We Improve Transfer of Outcomes from Randomized Clinical Trials to Clinical Practice with Disease-Modifying Drugs in Alzheimer's Disease?

Publisher： Karger

E-ISSN： 1660-2862|13|2-3|197-199

ISSN： 1660-2854

Source： Neurodegenerative Diseases, Vol.13, Iss.2-3, 2013-08, pp. : 197-199

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Expanding the Multipotent Profile of Huprine-Tacrine Heterodimers as Disease-Modifying Anti-Alzheimer Agents

By  

Neurodegenerative Diseases, Vol. 10, Iss. 1-4, 2012-01 ,pp. : 96-99

Karger

Access to resources Recommend Favorite

Clinical Trials in ALS: What Did We Learn from Recent Trials in Humans?

By  

Neurodegenerative Diseases, Vol. 2, Iss. 3-4, 2006-01 ,pp. : 208-214

Karger

Access to resources Recommend Favorite

Randomized response‐adaptive designs in clinical trials

By  

BIOMETRICS, Vol. 71, Iss. 1, 2015-03 ,pp. : 274-277

John Wiley & Sons Inc

Access to resources Recommend Favorite

We Can Treat Alzheimer's Disease Successfully in Mice but Not in Men: Failure in Translation? A Perspective

By  

Neurodegenerative Diseases, Vol. 13, Iss. 2-3, 2014-01 ,pp. : 147-150

Karger

Access to resources Recommend Favorite

Parallel Gene Expression Profiling of Mantle Cell Lymphoma - How Do We Transform ´Omics Data into Clinical Practice

By  

Current Genomics, Vol. 8, Iss. 3, 2007-05 ,pp. : 171-179

Bentham Science Publishers

Access to resources Recommend Favorite